● Recruiting

A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.

Condition: Breast Cancer · Breast Cancer Metastatic · Sponsor: ExpreS2ion Biotechnologies

PhasePhase 1

Planned participants40

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without \[adjuvant\], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Bent U. Frandsen · +4522221019 · info@expres2ionbio.com

Always discuss trial participation with your own doctor first.

Locations (3)

Medical University of Graz	Graz, Austria	Recruiting
Ordensklinikum Linz GmbH Barmherzige Schwestern	Linz, Austria	Recruiting
Medical University Of Vienna	Vienna, Austria	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06746688